No

Ovulation Stimulator

Induction of ovulation in patients with polycystic ovarian disease and to stimulate the development of multiple oocytes

X

Hypersensitivity to urofollitropin; high levels of both LH and FSH indicating primary ovarian failure; uncontrolled thyroid or adrenal dysfunction; organic intracranial lesion such as a pituitary tumor; presence of any cause of infertility other than anovulation, unless the patient is a candidate for in vitro fertilization; abnormal bleeding of undetermined nature; ovarian cysts or enlargement not due to polycystic ovarian disease; pregnancy (may cause fetal harm)

Use lowest dose possible to avoid abnormal ovarian enlargement. If hyperstimulation occurs, discontinue use and hospitalize patient. Use with caution in patients with a history of thromboembolism.

>10%:

Endocrine & metabolic: Ovarian enlargement or ovarian cysts

Local: Edema at injection site, pain at injection site

1% to 10%:

Cardiovascular: Arterial thromboembolism

Central nervous system: Fever, chills

Dermatologic: Rash or hives

Endocrine & metabolic: Breast tenderness

Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea

Miscellaneous: Hyperstimulation syndrome

Symptoms of overdose include possible hyperstimulation and multiple gestations. Supportive care to maintain fluid and electrolyte imbalance may be needed.

No data reported

Preparation of follicle-stimulating hormone 75 IU with <1 IU of luteinizing hormone (LH) which is isolated from the urine of postmenopausal women. Follicle-stimulating hormone plays a role in the development of follicles. Elevated FSH levels early in the normal menstrual cycle are thought to play a significant role in recruiting a cohort of follicles for maturation. A single follicle is enriched with FSH receptors and becomes dominant over the rest of the recruited follicles. The increased number of FSH receptors allows it to grow despite declining FSH levels. This dominant follicle secretes low levels of estrogen and inhibin which further reduces pituitary FSH output. The ovarian stroma, under the influence of luteinizing hormone, produces androgens which the dominant follicle uses as precursors for estrogens.

Serum half-life, elimination: 3.9 hours and 70.4 hours (FSH has two half-lives)

Adults: Female: S.C.: 75 units/day for 7-12 days, used with hCG may repeat course of treatment 2 more times

Give via micron filter needle

No information available to require special precautions

No effects or complications reported

This drug must be given according to a set schedule. Maintain a calendar of treatment days and ovulation days. Engage in intercourse daily beginning on the day prior to hCG administration until ovulation is apparent. Be aware that multiple births may result. You may experience flushing, abdominal distention, or breast tenderness. Report pain or heat in calves, fever, chills, rash, or difficulty breathing. Pregnancy/breast-feeding precautions: Inform prescriber if pregnant. Do not breast-feed.

Stability: Protect from light; refrigerate at 3°C to 25°C (37°F to 77°F)

Injection: 0.83 mg [75 units FSH activity] (2 mL); 1.66 mg [150 units FSH activity]